CCRL1 anticorps (PE)

N° du produit ABIN2662412

Cet anticorps anti-CCRL1 Monoclonal Souris conjugué à PE (Clone 13E11) (ABIN2662412) détecte spécifiquement CCRL1 dans FACS. L’anticorps est réactif avec des échantillons de Humain.

Aperçu rapide pour CCRL1 anticorps (PE) (ABIN2662412)

Antigène: CCRL1 (Chemokine (C-C Motif) Receptor-Like 1 (CCRL1))

Reactivité: Humain

Hôte: Souris

Clonalité: Monoclonal

Conjugué: Cet anticorp CCRL1 est conjugé à/à la PE

Application: Flow Cytometry (FACS)

Clone: 13E11

Détail du produit anti-CCRL1 anticorps (PE)

Purification: The antibody was purified by affinity chromatography and conjugated with PE under optimal conditions. The solution is free of unconjugated PE and unconjugated antibody.

Isotype: IgG2b kappa

Information d'application

Indications d'application: Optimal working dilution should be determined by the investigator.

Restrictions: For Research Use only

Stockage

Buffer: Phosphate-buffered solution, pH 7.2, containing 0.09 % sodium azide and 0.2 % (w/v) BSA .

Agent conservateur: Sodium azide

Précaution d'utilisation: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Conseil sur la manipulation: Protect from prolonged exposure to light. Do not freeze.

Stock: 4 °C

Stockage commentaire: The antibody solution should be stored undiluted between 2°C and 8°C.

Détails sur CCRL1

Antigène: CCRL1 (Chemokine (C-C Motif) Receptor-Like 1 (CCRL1))

Autre désignation: CCX-CKR

Sujet: Human CCX-CKR, also known as CCRL1, is a 40 kD, G-protein-coupled, seven transmembrane receptor. CCRL1 is a decoy receptor for CCL2, CCL8, CCL13, CCL19, CCL21 and CCL25 that regulates chemotaxis of lymphocytes and cancer cells. Chemokine binding by CCX-CKR causes its internalization, reducing levels of available chemokine, and thus regulating migration of lymphocytes and cancerous cells. CCX-CKR is expressed by stromal cells of skin-draining lymph nodes, thymic epithelial cells, and immature dendritic cells (DCs). A low CCX-CKR expression in tumor cells correlates with a poor survival rate of breast cancer patients.